Pharmacokinetic interaction studies of co-administration of ticagrelor and atorvastatin or simvastatin in healthy volunteers
Authors:
- 25 August 2012
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 69 (3) , 477-487
Abstract
Interactions between ticagrelor and atorvastatin or simvastatin were investigated in two-way crossover studies. Both studies were open-label for statin; the atorvastatin study was placebo-controlled for ticagrelor. For atorvastatin, volunteers (n = 24) received ticagrelor (loading dose 270 mg; 90 mg twice daily, 7 days) or placebo, plus atorvastatin calcium (80 mg; day 5). For simvastatin, volunteers (n = 24) received simvastatin 80 mg, or ticagrelor (loading dose 270 mg; 180 mg twice daily, 7 days) plus simvastatin (80 mg; day 5). In each study, volunteers received the alternate treatment after washout (≥7 days). Ticagrelor increased mean atorvastatin maximum plasma concentration (Cmax) and area under the plasma concentration-time curve from zero to infinity (AUC) by 23 % and 36 %, respectively. Simvastatin Cmax and AUC were increased by 81 % and 56 % with ticagrelor. Ticagrelor also increased Cmax and AUC of analysed atorvastatin metabolites by 13–55 % and 32–67 %, respectively, and simvastatin acid by 64 % and 52 %, respectively. Co-administration of ticagrelor with each statin was well tolerated. Exposure to ticagrelor and its active metabolite, AR-C124910XX, was generally unchanged by a single dose of either statin, except for a minor increase in ticagrelor Cmax in the presence of simvastatin. Effects of ticagrelor on atorvastatin pharmacokinetics were modest and unlikely clinically relevant, while with simvastatin, changes were slightly larger, and simvastatin doses >40 mg with ticagrelor should be avoided.Keywords
This publication has 39 references indexed in Scilit:
- Development of a Population Pharmacokinetic Model for Atorvastatin Acid and Its Lactone MetaboliteClinical Pharmacokinetics, 2010
- Absorption, Distribution, Metabolism, and Excretion of Ticagrelor in Healthy SubjectsDrug Metabolism and Disposition, 2010
- Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteersBritish Journal of Clinical Pharmacology, 2010
- Ticagrelor: The First Reversibly Binding Oral P2Y12 Receptor AntagonistCardiovascular Therapeutics, 2009
- SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acidPharmacogenetics and Genomics, 2006
- Statin Safety and Drug Interactions: Clinical ImplicationsThe American Journal of Cardiology, 2006
- Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitorsThe American Journal of Cardiology, 2004
- Clinical Pharmacokinetics of AtorvastatinClinical Pharmacokinetics, 2003
- Effect of Age and Gender on Pharmacokinetics of Atorvastatin in HumansThe Journal of Clinical Pharmacology, 1996
- Clinical Pharmacokinetics and Practical Applications of SimvastatinClinical Pharmacokinetics, 1993